TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02723604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
Study: NCT00775502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIW-8962
Description: Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
Study: NCT03961126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of autologous fatty tissue associated with autologous platelet-rich plasma.
Description: Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (clobetasol 0.05%)
Description: Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
Study: NCT01918189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral pain self-management intervention Pain EASE
Description: 10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
Study: NCT03868358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks
Study: NCT05631444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-based therapy
Description: One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
Study: NCT01608724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: oral, 5 mg once a day (Q.D.)
Study: NCT02457182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual medical therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual medical therapy
Study: NCT05631444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-based therapy
Description: One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cell-based therapy
Description: One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
Study: NCT05430061

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: slowly digestible carbohydrate
Description: carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: slowly digestible carbohydrate
Description: carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
Study: NCT02216526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil® Restoraderm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excipial
Study: NCT04104906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control training
Description: The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The exercise group
Description: the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
Study: NCT02690142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035 i.v.
Description: Single dose i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035 i.v.
Description: Single dose i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035 s.c.
Description: Single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035 s.c.
Description: Single dose s.c.
Study: NCT00181753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope study
Description: 7 hours of primed constant infusion of stable isotope tracers.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope study
Description: 7 hours of primed constant infusion of stable isotope tracers.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant stable isotope tracer infusion.
Study: NCT00529633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide by mouth at night for a total of 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo by mouth at night for a total of 24 weeks
Study: NCT03621280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole up to 1200 mg daily
Study: NCT02553629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study: NCT02801786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The arm will be composed of 03 women who used placebo capsules and gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The arm will be composed of 03 women who used placebo capsules and gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The arm will be composed of 03 women who used placebo capsules and gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
Study: NCT01337570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal Ring containing no drug substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine
Study: NCT04264000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma
Description: Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose
Description: Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
Study: NCT00181753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant stable isotope tracer infusion.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant stable isotope tracer infusion.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant stable isotope tracer infusion.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours primed constant infusion of stable isotope tracer study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours primed constant infusion of stable isotope tracer study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours primed constant infusion of stable isotope tracer study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours primed constant infusion of stable isotope tracer study
Study: NCT03107117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Counseling
Description: two computer counseling online programs for a teen and a parent

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: A referral for substance use counseling
Study: NCT03573063

Intervention type: OTHER
Group type: OTHER
Intervention: Androgen metabolism after starvation
Description: The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant.
Study: NCT03423277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy Stretch Toolkit
Description: Study the use of novel intraoral tools for management of facial burns and other facial disorders
Study: NCT02336438

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucomannan
Description: Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
Study: NCT04001400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20mg bid
Description: Rabeprazole 20mg tablet b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 20mg qd
Description: Rabeprazole 20mg tablet q.d.
Study: NCT01932684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath-Stacking
Description: We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Description: We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5000 Voldyne ® Sherwood Medical, USA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone face mask
Study: NCT04397380

Intervention type: DEVICE
Intervention: Thermography
Description: Measure Temperature using Thermal Camera

Intervention type: DEVICE
Intervention: Tympanic Temperature
Description: Measure Temperature using Tympanic Temperature
Study: NCT01326442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low glycemic diet
Description: a low glycemic diet, calorie restricted with exercise sessions 3 times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low glycemic diet
Description: a low glycemic diet, calorie restricted with exercise sessions 3 times per week

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D omega-3
Description: 2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
Study: NCT02797821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asfotase alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asfotase alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Study: NCT01337063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentored medication reconciliation quality improvement
Description: Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls.
Study: NCT04252612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
Study: NCT03632252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered ankle prosthesis
Description: This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
Study: NCT03800862

Intervention type: DEVICE
Intervention: CT-FFR and CTP
Description: Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
Study: NCT03057756

Intervention type: COMBINATION_PRODUCT
Intervention: Km+ Mfx+ Pto + H + Cfz +E+Z
Description: Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
Study: NCT00811460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sc for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 300micrograms/day sc for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 800 micrograms/day sc for 2 days
Study: NCT04039932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLAME
Description: The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
Study: NCT03493646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: 100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
Study: NCT01518712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Study: NCT05181488

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy, IORT
Description: A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
Study: NCT05321290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Therapy Program
Study: NCT03880357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Scalp Suspension 0.064%;0.0005%
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex®
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical suspension
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Study: NCT02455167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprivir (SMV)
Description: Experimental Single arm study. All participants will get the same treatment.
Study: NCT01518712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study: NCT02455167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)
Description: Experimental Single arm study. All participants will get the same treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Experimental Single arm study. All participants will get the same treatment.
Study: NCT01966146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echography GE Healthcare Vivid E9
Description: Echography GE Healthcare Vivid E9

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echography GE Healthcare Vivid E9
Description: Echography GE Healthcare Vivid E9
Study: NCT06184802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU+Multisensory room
Description: Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
Study: NCT02712788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02485015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Killer Cells
Description: Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.

Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Advanced gastric cancer patients take Apatinib 850mg qd by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
Study: NCT02286609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.